Related Experiment Video
Updated: Jan 9, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
The implication of aberrant NRF2 activation in management of female cancers
Mankgopo Kgatle1,2,3, Saidon Mbambara1,2,4, Olalekan Fadebi1,2
1Nuclear Medicine Research Infrastructure, Department of Basic and Translational Research, Pretoria, South Africa.
Abstract:
The overactivation of NRF2 (Nuclear factor erythroid 2-related factor 2) in female malignancies is an emerging field of study with significant implications for treatment efficacy. NRF2 plays a pivotal role in managing inflammation-induced oxidative stress, which is crucial components of the tumor microenvironment. Acting as a transcription factor and basic leucine zipper protein, it regulates the expression of various antioxidant genes that safeguard cells from oxidative stress and damage. While NRF2 activation is beneficial for the survival of normal cells, its overactivation in cancer cells can enhance tumor cell survival, proliferation, and resistance to treatments. Importantly, NRF2 has a dual context-dependent role, functioning as a tumor suppressor when transiently activated in normal cells to prevent carcinogenesis, but as an oncogene when persistently activated in established tumors. Understanding NRF2's transcriptional alterations and developing targeted therapies could improve cancer management, prognosis and treatment outcomes, making it a promising target for precision oncology. This review aims to provide a comprehensive overview of NRF2 activation in female malignancies, including cervical, endometrial, ovarian, vaginal, vulvar and, breast cancers, and its association with chemoresistance, highlighting challenges and opportunities for developing more effective cancer treatments.
Insights
Overactivation of Nuclear factor erythroid 2-related factor 2 (NRF2) promotes cancer cell survival and treatment resistance in female malignancies. Targeting NRF2 offers a promising strategy for improving precision oncology outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor regulating antioxidant genes.
- NRF2 plays a dual role in cancer: tumor suppressor in normal cells and oncogene in established tumors.
- NRF2 overactivation in the tumor microenvironment contributes to inflammation-induced oxidative stress and cancer progression.
Purpose of the Study:
- To provide a comprehensive overview of NRF2 activation in female malignancies.
- To explore the association between NRF2 and chemoresistance in these cancers.
- To highlight challenges and opportunities for developing targeted NRF2 therapies.
Main Methods:
- Literature review of NRF2's role in cervical, endometrial, ovarian, vaginal, vulvar, and breast cancers.
- Analysis of NRF2's transcriptional alterations and its impact on treatment efficacy.
- Examination of NRF2's context-dependent functions in carcinogenesis and tumor progression.
Main Results:
- NRF2 overactivation enhances tumor cell survival, proliferation, and treatment resistance.
- Persistent NRF2 activation acts as an oncogene in established tumors.
- NRF2's role varies depending on its activation status and cellular context.
Conclusions:
- Understanding NRF2's role is crucial for improving cancer management and prognosis.
- Targeted therapies against NRF2 present a promising avenue for precision oncology.
- Further research into NRF2 alterations can lead to more effective cancer treatments.
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
